{"title":"对抗前列腺癌靶向治疗的双头龙。","authors":"Scott Wilkinson, Adam G Sowalsky","doi":"10.1080/23723556.2020.1745037","DOIUrl":null,"url":null,"abstract":"<p><p>Neoadjuvant intense androgen deprivation therapy for high-risk localized prostate cancer is an emerging but unproven treatment paradigm that is hoped to delay or prevent disease recurrence. We found that a patient enrolled in a clinical trial harbored two completely independent prostate cancers that responded differently to this therapy.</p>","PeriodicalId":520710,"journal":{"name":"Molecular & cellular oncology","volume":" ","pages":"1745037"},"PeriodicalIF":0.0000,"publicationDate":"2020-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23723556.2020.1745037","citationCount":"1","resultStr":"{\"title\":\"Battling the two-headed dragon of prostate cancer targeted therapy.\",\"authors\":\"Scott Wilkinson, Adam G Sowalsky\",\"doi\":\"10.1080/23723556.2020.1745037\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Neoadjuvant intense androgen deprivation therapy for high-risk localized prostate cancer is an emerging but unproven treatment paradigm that is hoped to delay or prevent disease recurrence. We found that a patient enrolled in a clinical trial harbored two completely independent prostate cancers that responded differently to this therapy.</p>\",\"PeriodicalId\":520710,\"journal\":{\"name\":\"Molecular & cellular oncology\",\"volume\":\" \",\"pages\":\"1745037\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-04-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1080/23723556.2020.1745037\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Molecular & cellular oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/23723556.2020.1745037\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2020/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular & cellular oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/23723556.2020.1745037","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
Battling the two-headed dragon of prostate cancer targeted therapy.
Neoadjuvant intense androgen deprivation therapy for high-risk localized prostate cancer is an emerging but unproven treatment paradigm that is hoped to delay or prevent disease recurrence. We found that a patient enrolled in a clinical trial harbored two completely independent prostate cancers that responded differently to this therapy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
